Kornimate/medical-research-clean huggingface dataset:
ketorolac vs oxycodone for great toe arthrodesis

Conditions: Arthrodesis

Summary: this study reviews if taking ketorolac, after a joint fusion procedure, can decrease the need for taking oxycodone (standard of care) for pain relief. the study also investigates if ketorolac affects bone healing after surgery.

this study reviews if taking ketorolac, after a joint fusion procedure, can decrease the need for taking oxycodone (standard of care) for pain relief. the study also investigates if ketorolac affects bone healing after surgery.

Eligibility criteria:
inclusion criteria: * age 18 - 75 years. * women of childbearing potential must have a negative serum or urine pregnancy test results within 24 hours before the first dose of ketorolac. * primary elective great toe mtp arthrodesis (cpt 28750). other forefoot procedures often performed in conjunction with toe fusion will be included (cpt codes 28308, 28285, 28270). exclusion criteria: * chronic pain syndrome, crps or fibromyalgia * revision procedures * use of allograft bone at the fusion site * tobacco use * diabetes * narcotic abuse or iv drug abuse * any cpt codes involving the midfoot, hindfoot, and/or ankle * unable to take nsaids secondary to medical comorbidities such as kidney disease (impaired renal function with crcl ≤ 50 ml/min) or gastric ulcers * weight \< 50 kg * does not speak or read english * if pregnant or planning to become pregnant or breastfeeding * non-independent dweller (prisoner)

Keywords: big toe arthrodesis big toe joint fusion
mental health assessment project on the thailand-burma border

Conditions: Depression; Anxiety; Posttraumatic Stress

Summary: the aim of the study is to determine the effectiveness of a transdiagnostic psychotherapy intervention - namely, common elements treatment approach (ceta) - in reducing the severity of mental health symptoms experienced by torture and violence survivors displaced from burma into thailand. specifically, the intervention seeks to measure reductions (if any) in symptoms of depression and trauma.

the study is part of an award by the usaid victims of torture fund (usaid/vtf) to jhu to work with local and international organizations serving survivors of torture and systematic violence. for this study, the intent is to assist in the design, implementation, monitoring, and evaluation of programming to understand and address the psychosocial needs of burmese displaced across the thai/burma border who are living in the area of mae sot, tak province in thailand. specifically this project involves collaboration with the burma border projects (bbp), the mae tao clinic (mtc), the assistance association for political prisoners (aapp), and social action for women (saw), to help improve the quality and effectiveness of psychosocial and mental health programs. the common elements treatment approach (ceta) is a transdiagnostic treatment approach developed for delivery by lay counselors in low and middle income countries (lmic) with few mental health professionals. ceta was designed to treat symptoms of common mental health disorders including depression, pts, and anxiety, and to provide skills to deal with life stressors. includes engagement, psychoeducation, anxiety management strategies, behavioral activation, cognitive coping/restructuring, imaginal gradual exposure, suicide/homicide/danger assessment and planning, and screening and brief intervention for alcohol.

Eligibility criteria:
inclusion criteria: * burmese national, 18 or over, living in thailand outside of refugee camps, meets or exceed the algorithm for the hopkins symptoms checklist 25 (hscl-25) depression subscale and/or the algorithm for the harvard trauma questionnaire (htq) posttraumatic stress scale. exclusion criteria: * not burmese national, under 18, not living in thailand outside of refugee camps, does not meet meet or exceed the algorithm for the hopkins symptoms checklist 25 (hscl-25) depression subscale and/or the algorithm for the harvard trauma questionnaire (htq) posttraumatic stress scale; active psychosis
evaluation of a novel technique to investigate cas piezo electric sensors

Conditions: Carotid Artery Disease

Summary: the proposed study is evaluating a novel technology, carotid stenotic scan (css), developed by the sponsor, cvr global. study design. this is a prospective cohort study that will compare a new application of a technology, the css device, to reference standards for assessment of carotid disease.

the overall objectives of this study are to demonstrate that the carotid stenotic scan (css) can accurately detect significant carotid artery stenosis. secondary objective is to relate changes in css signal to different degrees of stenosis. we obtain a "proof of concept" if the device correlates strongly with the established classification of atherosclerotic carotid disease derived various imaging modalities including magnetic resonance angiography (mra) and computer tomographic angiography (cta), conventional angiography, or carotid ultrasound.

Eligibility criteria:
inclusion criteria: * subjects over 18 referred for carotid duplex ultrasound. * subjects over 18 referred for ct angiography, mr angiography, or conventional angiography of the carotid arteries exclusion criteria: * previous history of carotid endarterectomy, carotid artery stent * previous surgery involving the neck (including thyroidectomy or parathyroidectomy) * patients with prosthetic heart valve * patients unable to provide informed consent.
effect of downhill training on ankle joint

Conditions: Obesity

Summary: downhill training help to improve musculoskeletal condition. applying downhill training could help obese children by improving their muscular strength.

the current study aimed to find the effect of downhill training on the ankle isokinetic parameters of obese children. there were two experimental groups, the first received level walking while the second received downhill training. the ankle isokinetic parameters were assessed pre and post-intervention for 6 weeks.

Eligibility criteria:
inclusion criteria: * body mass index percentile 95% or more * age ranged from 8-12 year * student in one of taif's elementary schools exclusion criteria: * suffering from any musculoskeletal problem or chronic disease. * engaged in regular sports activities during the last 6 months
extracorporeal shock wave therapy for the treatment of ischemic heart disease

Conditions: Refractory Angina Pectoris

Summary: low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. the hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.

low intensity shockwaves (1/10 the ones used in lithotripsy) are delivered to myocardial ischemic tissue. shockwaves are created by a special generator and are focused using a shockwave applicator device. the treatment is guided by standard echocardiography equipment. the shockwaves are delivered in synchronization with patient r-wave to avoid arrhythmias. the treatment is painless. at first, the patient undergoes stress-echocardiography testing to identify the hypokinetic areas (ischemic areas). following that, the ischemic areas sre treated with shockwaves. several treatments are required for optimal results.

Eligibility criteria:
inclusion criteria: * patient is diagnosed with chronic stable angina pectoris. diagnosis is based on medical history, complete physical evaluation. * patient has documented myocardial segments with reversible ischemia. * patient is classified in ap ccs of iii-iv. * patient should be on a stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment. * patient demonstrates exercise tolerance capacity of no higher than 125 w on a modified bruce treadmill exercise test until presence of clinical symptoms (i.e. angina, st-depression). * patient demonstrates exercise tolerance time and stability averaging no more than 25% of each other (the tests will be performed within two weeks and at least a day different between the two). * patient has documented epicardial coronary artery disease not amenable to angioplasty or cabg. * patient has signed an irb approved informed consent form. * patient's condition should be stable and should have a life expectancy of \>12 months. patient's current and past medical condition and status will be assessed using previous medical history, physical evaluation, and the physicians (principle investigator's) medical opinion. exclusion criteria: * patient is pregnant * patient has chronic lung disease including emphysema and pulmonary fibrosis. * patient has active endocarditis, myocarditis or pericarditis. * patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization, or any eswt machine of a competitor company within 3 months of entry into the study. * patients who are unwilling or unable to cooperate with study procedure

Keywords: extracorporeal shockwave therapy myocardial ischemia refractory angina
autologous bone marrow stem cells for children with autism spectrum disorders

Conditions: Autism; Autism Spectrum

Summary: the purpose of this study is to determine whether the plasticity of autologous intrathecal hematopoietic cells would improve the neurologic and the social skills of pediatric patients with autism spectrum disorders.

there is accumulating evidence that shows that the administration of hematopoietic cells into the brain in the patients with spectrum autism could help in the physiopathology of the illness. it has been found that after introducing hematopoietic cells in the subarachnoid space of the spinal cord, these cells may be transported through the cerebrospinal fluid and can be delivered more efficiently to the injured area, when compared to the intravenous route. patients will be stimulated for 3 consecutive days with granulocyte colony stimulating factor (g-csf) and then their bone marrow will be harvested according to their weight. bone marrow will be processed in order to obtain cd34+ cells and minimize the amount of red blood cells. an inoculum of 5 to 10ml of stem cells will be infused intrathecally. patients will be evaluated with two scales "cars" and the "idea" also we will check the clinical history. on days 0, 30 and 180.

Eligibility criteria:
inclusion criteria: * children with autism spectrum dsm4-tr exclusion criteria: * patients with neurodegenerative or autoimmune diseases. * patients with active infection in any organ or tissue at the time of entering the study, the onset of stimulation with g-csf or at the procedure. * patients who do not sign the informed consent form.

Keywords: autism autism spectrum stem cells children
early surgical fixation of low-velocity hip fractures in patients with direct oral anticoagulation

Conditions: Hip Fractures

Summary: prospective cohort study on patients with intertrochanteric fractures under direct oral anticoagulation (doac) therapy undergoing early surgical fixation (within 24 hours). the primary aim of this study is to evaluate the reduction of the peri operative blood loss. the secondary aim is to assess the influence of early surgical fixation of intertrochanteric fractures in patients with doac therapy on the 30-day and 1-year mortality. moreover, the prospective cohort group of patients will be compared with a retrospectively analyzed age-, gender- and fracture-type-matched control group of patients who underwent delayed surgical fixation from january 2014 to december 2018 (≥ 48 hours).


Eligibility criteria:
inclusion criteria: prospective cohort study: patients with intertrochanteric fractures that need a surgical fixation and under treatment with a doac medication control group: patients with intertrochanteric fractures under doac medication with a delayed surgical fixation from january 2014 to december 2018 (≥ 48 hours after the trauma) exclusion criteria: prospective cohort group: * patients with multiple fractures * acute heart failure, kidney and lung failure and * other concomitant diseases which prevent prompt fixation retrospective cohort group: patients with delayed surgical fixation due to other causes than doac medication (e.g. multimorbidity, acute myocardial infarction, acute heart, lung or kidney failure)
using financial incentives and screening to increase engagement with mental health services among college students in chennai, india

Conditions: Depression/Anxiety

Summary: this study will evaluate the effectiveness of interventions to increase engagement with mental health services among a sample of college students in chennai, india. the study is being conducted in partnership with an arts and science college for women in chennai. the sample will be recruited within classrooms, during college hours. all students present in the classroom per the allotted time will be introduced to the study. the research team will obtain consent from those interested after screening them for age eligibility (between the ages of 18 and 30 years). study participants will then complete a baseline survey including questions around demographics, perceptions of their own mental health, mental health treatment history, and the phq-ads, a standardized composite screening tool for depression and anxiety. the experimental design is an rct with 4 groups, randomized at the individual level: (1) a control group, which will watch a video with information about mental health and be able to access therapy in college and at scarf, a mental health center in chennai, at no cost for the duration of the study; (2) a screening group, in which, in addition to the interventions in the control group, students will be informed whether their responses to the phq-ads questions fit in the standard risk categories of no, mild, moderate, or severe distress and corresponding recommendations for whether to make an appointment with a counselor/therapist; (3) a rewards group, in which, in addition to the interventions in the control group, students will be provided with a cash payment for attending their first therapy session; and (4) a combined screening and rewards group. the investigators will measure interest in, and take-up of, therapy at the individual level.


Eligibility criteria:
inclusion criteria: * aged 18-30 * are present in the classrooms, * consent to participate in the study exclusion criteria: none
efficacy & safety study of recombinant human erythropoietin -alpha, in patients with anemia of chronic renal failure

Conditions: Anemia

Summary: to establish the efficacy and safety of rhu-epo-alpha in patients with anemia of chronic renal failure.

despite impressive advances in the safety of the blood supply, the search for therapeutic alternatives to blood continues. recombinant human erythropoietin (rhu-epo), along with iron, vitamin b12, and folic acid, has been recommended as a specific medication that should be used instead of blood transfusion if the clinical condition of the patient permits sufficient time for these agents to promote erythropoiesis. in normal physiological conditions erythropoietin is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. rhu-epo is a glycoprotein which stimulates red blood cell production. epoetin alfa, a 165 amino acid glycoprotein manufactured by recombinant dna technology, has the same biological effects as endogenous rhu-epo.

Eligibility criteria:
inclusion criteria: * patients between 18 to 70 yrs of age of either sex. * crf patients who are epo naïve or have been off epo or similar erythropoietic drugs for more than 4 weeks, falling with-in ckd stage iii to v. * patients who are willing to give the consent * patient with anemia of chronic renal failure with hb \< 10. exclusion criteria: * patients who are known hypersensitive to rhu-epo. * patient's with history of anemia due to causes other than anemia of crf. * patient's with history of active infections, hemoglobinopathies, neoplastic diseases, and hiv infection. * patient's with history of g.i. bleeding (overt or occult). * patient's with history of serious or unstable medical or psychological conditions that could compromise the patient's safety or successful trial participation. * patients with abnormal liver function test. however, patients with hbsag and hcv positive shall be included provided their transaminases are normal. * female patient's of child bearing potential and not having undergone permanent sterilization procedures. pregnant and lactating female patients. * patients unwilling or unable to comply with the study procedures. chronic alcoholic or drug abuse patients

Keywords: anemia
cost-effectiveness of reduction mammaplasty

Conditions: Breast,Hypertrophy; Cost-effectiveness

Summary: several works show breast hypertrophy as pain cause, postural alterations, dermatitis and decrease of the functional capacity and of the self-esteem. the economical evaluations are destined to esteem the costs in alternative ways of attendance to the health, comparing, for instance, clinical strategies with surgical strategies. objective: to analyze cost-effectiveness in reduction mammaplasty.

1. design: this is a primary, prospective, analytical, controlled study in humans. 2. settings: data will be collected at the plastic surgery and orthopedic and traumatology outpatient clinics of the samuel libânio general hospital (hospital das clínicas samuel libânio, hcsl), pouso alegre, mg, brazil, in july/2008-december 2009. 3. participants: fifty women with breast hypertrophy (25 study group and 25 control group) according to the sacchini index,12 aged 18 to 59 years, were consecutively selected to participate in this study. pregnant women, and patients who gave birth or were breastfeeding less than one year before the beginning of the study, as well as patients with uncontrolled systemic diseases, acute diseases, breast asymmetry, who had undergone breast or spine surgery, and who had body-mass index (bmi) lower than 18.5 kg/m2 (low body weight) or greater than 30 kg/m2 (obese women) were excluded from the study. 4. instruments: pain intensity in the cervical, dorsal and lumbar regions of the back has been assessed using a visual analogue scale (vas). also will be used sf36, haq 20 and sf-6d.

Eligibility criteria:
inclusion criteria: * women with breast hypertrophy according to the sacchini index exclusion criteria: * pregnant women * patients who gave birth or were breastfeeding less than one year before the beginning of the study * patients with uncontrolled systemic diseases, acute diseases, or breast asymmetry * patients who had undergone breast or spine surgery * patients who had body-mass index (bmi) lower than 18.5 kg/m2 (low body weight) or greater than 30 kg/m2 (obese women)

Keywords: quality-adjusted life years:a measurement index cost-benefit analysis:a method of comparing costs mammaplasty qaly health-related quality of life cost-effectiveness breast
offering cervical cancer screening to older women

Conditions: Uterine Cervical Neoplasm; Uterine Neoplasm; Uterine Cervical Disease; Mass Screening

Summary: this study evaluates the effect and feasibility of expanding the target population in the danish cervical cancer screening program to include women aged 65 to 69 years. the study also evaluates if hpv self-sampling constitutes an appropriate screening method among older women.

the study is a nationwide population-based prospective cohort study embedded in the routine cervical cancer screening program in the central denmark region. the study includes all 65 to 69 years old danish women with no record of a cervical cytology sample or screening invitation within the last five years. furthermore, the women are not registered as ineligible for screening, eg due hysterectomy. eligible women residing in the central denmark region are allocated to the intervention group (n=20,000), while women residing in the other four danish regions are allocated to the control group receiving standard care (n=71,500), which for this group is low-level opportunistic screening at the general practitioner (gp). the intervention group are invited for hpv-based screening by the gp or to request a self-sampling kit.

Eligibility criteria:
inclusion criteria: * 65 to 69 years; * resident in denmark * no record of a cervical cytology or screening invitation in the past 5 years * not registered as ineligible for screening exclusion criteria: * death * migration to or from denmark * moving to or from the cdr * residing in the cdr, but having gp in another region * a record of hysterectomy

Keywords: hpv self-sampling, cervical cancer screening in older women
botulinum toxin a for treatment of catocholamine induced finger necrosis

Conditions: Catocholamine Induced Finger Necrosis

Summary: patients in the intensive care unit (icu) often require blood pressure support of vasoactive drugs such as amines. finger necrosis (so called "blue toe syndrome") is a well documented phenomena with incidence reaching as high as 60% in patients receiving vasopressin. botulinum toxin is a known muscle relaxant used for a variety of medical application. recently, several reports have demonstrated its effect in vasospastic disorders. it has also been in mice that when administered locally it has a local vasodilatory effect. the goal of this experiment is to compare the effect of botulinum toxin administered locally on amine induced finger necrosis.


Eligibility criteria:
inclusion criteria: * patients treated with vasoactive drugs (amines) and have finger/toe necrosis exclusion criteria: * sensitivity to drug (botox) ingredients. * active local limb infection * icu admission due to botulism * chronic muscular weakness disease, e.g., myasthenia gravis, als * age lower than 18

Keywords: botox catocholamine shock vasomotor vasopressin botulinum toxin
efficacy and safety of infliximab biosimilar in the treatment of resistant hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the aim of this clinical trial is to assess the efficacy and safety of infliximab-dyyb biosimilar in patients of resistant hidradenitis suppurativa. the main question it aims to answer are: * how effective is infliximab biosimilar in treating resistant hidradentis suppurativa * is infliximab biosimilar safe in these patients patients will receive weekly injections of infliximab biosimilar remsima, according to weight, for first 4 weeks, and then fortnightly for next 24 weeks. patients will be followed up at 4, 14 and 24 weeks for assessment of safety and efficacy

the aim of this clinical trial is to assess the efficacy and safety of infliximab-dyyb biosimilar in patients of resistant hidradenitis suppurativa. the main question it aims to answer are: * how effective is infliximab biosimilar in treating resistant hidradentis suppurativa * is infliximab biosimilar safe in these patients patients will receive weekly injections of infliximab biosimilar remsima, according to weight, for first 4 weeks, and then fortnightly for next 24 weeks. patients will be followed up at 4, 14 and 24 weeks for assessment of safety and efficacy. pre and post treatment hiscr, ihs4, dlqi scores and photos will be taken for comparison at week 0, 4, 14 and 24. details will be entered on predesigned proforma data analysis procedure: data will be entered and analyzed using spss 20. data will be stratified for role of effect modifiers.

Eligibility criteria:
inclusion criteria: * patients of hidradenitis suppurativa resistant to conventional therapy exclusion criteria: * immunocompromised patients * patients with connective tissue disorders * patients having chronic infections like heapatitis, hiv or tuberculosis * pregnant or lactating mothers * hypersensitivity to biologics

Keywords: hidradenitis suppurativa infliximab biosimilar efficacy safety